ID   DFCI-LU011
AC   CVCL_0F29
SY   DFCILU-011; DFCI-LU-011; Dana-Farber Cancer Institute-LUng 011
DR   ATCC; CRL-2883
DR   BioSample; SAMN03471809
DR   cancercelllines; CVCL_0F29
DR   Wikidata; Q54831031
RX   PubMed=16983123;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Unspecified (PubMed=16983123).
CC   Discontinued: ATCC; CRL-2883; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC=CRL-2883
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D5S818: 12
ST   D7S820: 9,12
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 16,17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 13
//
RX   PubMed=16983123; DOI=10.1200/JCO.2006.06.6126;
RA   Jackman D.M., Holmes A.J., Lindeman N.I., Wen P.Y.-C., Kesari S.,
RA   Borras A.M., Bailey C., de Jong F., Janne P.A., Johnson B.E.;
RT   "Response and resistance in a non-small-cell lung cancer patient with
RT   an epidermal growth factor receptor mutation and leptomeningeal
RT   metastases treated with high-dose gefitinib.";
RL   J. Clin. Oncol. 24:4517-4520(2006).
//